

# Michael A Nauck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5147965/publications.pdf>

Version: 2024-02-01

301  
papers

46,910  
citations

3149

92  
h-index

1792

211  
g-index

339  
all docs

339  
docs citations

339  
times ranked

23750  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 311-322.   | 13.9 | 5,070     |
| 2  | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. <i>Lancet, The</i> , 2006, 368, 1696-1705.  | 6.3  | 3,287     |
| 3  | Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. <i>Diabetes Care</i> , 2012, 35, 1364-1379.   | 4.3  | 3,077     |
| 4  | Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2015, 38, 140-149.   | 4.3  | 2,326     |
| 5  | Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.. <i>Journal of Clinical Investigation</i> , 1993, 91, 301-307.  | 3.9  | 1,401     |
| 6  | Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018, 392, 1519-1529.  | 6.3  | 1,179     |
| 7  | Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1993, 36, 741-744.  | 2.9  | 1,033     |
| 8  | Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 84-90.  | 4.3  | 991       |
| 9  | Glucagon-like peptide 1 (GLP-1). <i>Molecular Metabolism</i> , 2019, 30, 72-130.   | 3.0  | 850       |
| 10 | Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986, 63, 492-498.  | 1.8  | 752       |
| 11 | Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects. <i>Diabetes</i> , 1995, 44, 1126-1131.   | 0.3  | 721       |
| 12 | COVID-19 and diabetes mellitus: from pathophysiology to clinical management. <i>Nature Reviews Endocrinology</i> , 2021, 17, 11-30.  | 4.3  | 653       |
| 13 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 194-205. | 2.2  | 601       |
| 14 | Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015, 58, 429-442.  | 2.9  | 598       |
| 15 | Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. <i>Diabetes</i> , 1995, 44, 1126-1131.   | 0.3  | 559       |
| 16 | Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. <i>Lancet, The</i> , 2010, 375, 1447-1456.   | 6.3  | 534       |
| 17 | Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. <i>Lancet, The</i> , 2018, 392, 2180-2193.   | 6.3  | 528       |
| 18 | GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. <i>Molecular Metabolism</i> , 2021, 46, 101102.  | 3.0  | 518       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1239-1246.         | 1.8 | 515       |
| 20 | Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin. <i>Diabetes Care</i> , 2011, 34, 2015-2022.  | 4.3 | 479       |
| 21 | Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. <i>Lancet</i> , 2013, 381, 117-124.  | 6.3 | 466       |
| 22 | Incretin hormones: Their role in health and disease. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 5-21.  | 2.2 | 451       |
| 23 | Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1997, 273, E981-E988.   | 1.8 | 423       |
| 24 | Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 327-332.            | 1.8 | 422       |
| 25 | A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. <i>Diabetologia</i> , 2007, 50, 259-267.  | 2.9 | 422       |
| 26 | Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. <i>Circulation</i> , 2017, 136, 849-870.   | 1.6 | 415       |
| 27 | Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. <i>Diabetologia</i> , 2011, 54, 10-18.  | 2.9 | 402       |
| 28 | Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 76, 912-917. | 1.8 | 389       |
| 29 | Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 203-216.  | 2.2 | 322       |
| 30 | Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 76, 912-917.  | 1.8 | 318       |
| 31 | Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2719-2725.  | 1.8 | 315       |
| 32 | Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. <i>Lancet</i> , 2019, 394, 39-50.  | 6.3 | 315       |
| 33 | Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7-36) amide in type I diabetic patients. <i>Diabetes Care</i> , 1996, 19, 580-586.  | 4.3 | 310       |
| 34 | The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 525-536.   | 5.5 | 310       |
| 35 | Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance. <i>Diabetes</i> , 2008, 57, 678-687.   | 0.3 | 307       |
| 36 | Once-weekly abiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 289-297.                         | 5.5 | 293       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans. <i>Diabetes</i> , 2011, 60, 1561-1565.   | 0.3 | 291       |
| 38 | Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. <i>Diabetologia</i> , 1996, 39, 1546-1553.   | 2.9 | 286       |
| 39 | Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1335.   | 2.0 | 279       |
| 40 | Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects. <i>Diabetes</i> , 2004, 53, 654-662.   | 0.3 | 277       |
| 41 | Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5991-5997.  | 1.8 | 274       |
| 42 | Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. <i>Diabetologia</i> , 2003, 46, 798-801.  | 2.9 | 270       |
| 43 | Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications. <i>American Journal of Medicine</i> , 2011, 124, S3-S18.   | 0.6 | 255       |
| 44 | Glucagon-like peptide 1 (GLP-1) in biology and pathology. <i>Diabetes/Metabolism Research and Reviews</i> , 2005, 21, 91-117.   | 1.7 | 250       |
| 45 | Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 1163-1172. | 2.2 | 247       |
| 46 | Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. <i>Diabetologia</i> , 2006, 49, 452-458.  | 2.9 | 244       |
| 47 | Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). <i>Diabetes Care</i> , 2014, 37, 2149-2158.   | 4.3 | 236       |
| 48 | Glucagon-Like Peptide 2 Stimulates Glucagon Secretion, Enhances Lipid Absorption, and Inhibits Gastric Acid Secretion in Humans. <i>Gastroenterology</i> , 2006, 130, 44-54.  | 0.6 | 218       |
| 49 | Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. <i>Diabetologia</i> , 1995, 38, 720-725.   | 2.9 | 212       |
| 50 | Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 2763-2773.  | 4.3 | 211       |
| 51 | Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. <i>Regulatory Peptides</i> , 2008, 151, 123-129.  | 1.9 | 208       |
| 52 | Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes. <i>Diabetes</i> , 2001, 50, 2497-2504.  | 0.3 | 206       |
| 53 | Gastric Inhibitory Polypeptide: the neglected incretin revisited. <i>Regulatory Peptides</i> , 2002, 107, 1-13.   | 1.9 | 197       |
| 54 | Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 336-347.             | 2.2 | 194       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired $\beta^2$ -Cell Function?. <i>Diabetes</i> , 2010, 59, 1117-1125.   | 0.3 | 189       |
| 56 | A Critical Analysis of the Clinical Use of Incretin-Based Therapies. <i>Diabetes Care</i> , 2013, 36, 2126-2132.  | 4.3 | 189       |
| 57 | Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. <i>International Journal of Clinical Practice</i> , 2009, 63, 46-55. | 0.8 | 187       |
| 58 | Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. <i>American Heart Journal</i> , 2013, 166, 823-830.e5.  | 1.2 | 182       |
| 59 | Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes. <i>Diabetes</i> , 2004, 53, S190-S196.   | 0.3 | 177       |
| 60 | Glucagon-like Peptide 1 (7-36 hide) Secretion in Response to Luminal Sucrose from the Upper and Lower Gut: A Study Using $\alpha$ -Glucosidase Inhibition (Acarbose). <i>Scandinavian Journal of Gastroenterology</i> , 1995, 30, 892-896.  | 0.6 | 176       |
| 61 | Effects of Intravenous Glucagon-Like Peptide-1 on Gastric Emptying and Intra-gastric Distribution in Healthy Subjects: Relationships with Postprandial Glycemic and Insulinemic Responses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1916-1923.   | 1.8 | 172       |
| 62 | Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. <i>Regulatory Peptides</i> , 2005, 128, 135-148.  | 1.9 | 160       |
| 63 | Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin: A proof-of-concept study. <i>Diabetes Care</i> , 2010, 33, 1509-1515.   | 4.3 | 160       |
| 64 | MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?. <i>European Journal of Endocrinology</i> , 2019, 181, R211-R234.  | 1.9 | 156       |
| 65 | Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2438-2444.  | 4.3 | 152       |
| 66 | A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 231-241.  | 4.3 | 149       |
| 67 | Incretin-Based Therapies. <i>Diabetes Care</i> , 2009, 32, S223-S231.   | 4.3 | 143       |
| 68 | GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes. <i>Diabetes</i> , 2011, 60, 1270-1276.  | 0.3 | 141       |
| 69 | The evolving story of incretins (<sc>GIP</sc> and <sc>GLP</sc>â€1) in metabolic and cardiovascular disease: A pathophysiological update. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 5-29.   | 2.2 | 139       |
| 70 | Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1997, 105, 187-195.  | 0.6 | 133       |
| 71 | Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2006, 114, 417-423.   | 0.6 | 128       |
| 72 | Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 1501-1509.   | 4.3 | 126       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 938-946. | 2.2 | 126       |
| 74 | Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1695-1702.        | 1.8 | 125       |
| 75 | Unraveling the Science of Incretin Biology. <i>American Journal of Medicine</i> , 2009, 122, S3-S10.  | 0.6 | 123       |
| 76 | A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 216-227.  | 2.2 | 123       |
| 77 | Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 525-544.  | 5.5 | 121       |
| 78 | Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia. <i>Diabetes</i> , 2014, 63, 785-790.  | 0.3 | 120       |
| 79 | Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to $\pm$ -glucosidase inhibition (acarbose) in Type 2 diabetic patients. , 1998, 15, 485-491.   |     | 119       |
| 80 | Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 286, E621-E625.  | 1.8 | 117       |
| 81 | Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. <i>Diabetes Care</i> , 1998, 21, 1925-1931.   | 4.3 | 116       |
| 82 | Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. <i>European Journal of Pharmacology</i> , 2002, 440, 269-279.  | 1.7 | 115       |
| 83 | Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects. <i>Diabetes</i> , 2005, 54, 2212-2218.  | 0.3 | 113       |
| 84 | Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (<sc>AWARD</sc>): a randomized, phase III study. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 849-858.  | 2.2 | 108       |
| 85 | Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study. <i>Diabetes Care</i> , 2009, 32, 1237-1243.                 | 4.3 | 107       |
| 86 | Do GLP-1-Based Therapies Increase Cancer Risk?. <i>Diabetes Care</i> , 2013, 36, S245-S252.   | 4.3 | 106       |
| 87 | Insulinotropic Properties of Synthetic Human Gastric Inhibitory Polypeptide in Man: Interactions with Glucose, Phenylalanine, and Cholecystokinin-8. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 69, 654-662.   | 1.8 | 105       |
| 88 | Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. <i>Acta Diabetologica</i> , 1995, 32, 13-16.   | 1.2 | 105       |
| 89 | Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. <i>Regulatory Peptides</i> , 2004, 122, 209-217.  | 1.9 | 105       |
| 90 | The Dipeptidyl Peptidase 4 Inhibitor Vildagliptin Does Not Accentuate Glibenclamide-Induced Hypoglycemia but Reduces Glucose-Induced Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide Secretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4165-4171.   | 1.8 | 105       |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | The pathogenesis of NIDDM involves a defective expression of the GIP receptor. <i>Diabetologia</i> , 1997, 40, 984-986.  | 2.9 | 104       |
| 92  | Is glucagon-like peptide 1 an incretin hormone?. <i>Diabetologia</i> , 1999, 42, 373-379.  | 2.9 | 100       |
| 93  | Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. <i>British Heart Journal</i> , 2004, 90, 9-12.   | 2.2 | 96        |
| 94  | Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1111-1120.   | 2.2 | 93        |
| 95  | Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2020, 43, 1546-1552.   | 4.3 | 92        |
| 96  | The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E1118-E1123.  | 1.8 | 90        |
| 97  | Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without) Tj ETQq1 1 0.784314 rgBT / <i>Overlook and Metabolism</i> , 2015, 17, 1056-1064.  | 2.2 | 89        |
| 98  | Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. <i>Circulation</i> , 2022, 145, 575-585.   | 1.6 | 88        |
| 99  | Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. <i>Critical Care Medicine</i> , 2004, 32, 848-851.  | 0.4 | 87        |
| 100 | Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52-week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. <i>Diabetologia</i> , 2016, 59, 266-274. | 2.9 | 85        |
| 101 | Risk of pancreatitis in patients treated with incretin-based therapies. <i>Diabetologia</i> , 2014, 57, 1320-1324.   | 2.9 | 84        |
| 102 | The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. <i>Diabetologia</i> , 2005, 48, 608-611.   | 2.9 | 83        |
| 103 | Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. <i>Circulation</i> , 2018, 138, 2884-2894.   | 1.6 | 82        |
| 104 | Incretins and the development of type 2 diabetes. <i>Current Diabetes Reports</i> , 2006, 6, 194-201.  | 1.7 | 81        |
| 105 | Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and $\alpha$ -celsoglycemicâ€•Intravenous Glucose. <i>Diabetes</i> , 2014, 63, 663-674.   | 0.3 | 80        |
| 106 | Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. <i>Circulation</i> , 2018, 137, 2179-2183.  | 1.6 | 80        |
| 107 | Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. <i>Acta Diabetologica</i> , 1998, 35, 117-129.  | 1.2 | 75        |
| 108 | Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. <i>Diabetologia</i> , 2007, 50, 806-813.  | 2.9 | 75        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 699-704.   | 2.2 | 75        |
| 110 | Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects. <i>Diabetes</i> , 2004, 53, S220-S224.  | 0.3 | 73        |
| 111 | Plasma Glucose at Hospital Admission and Previous Metabolic Control Determine Myocardial Infarct Size and Survival in Patients With and Without Type 2 Diabetes: The Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). <i>Diabetes Care</i> , 2005, 28, 2551-2553. | 4.3 | 73        |
| 112 | GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial. <i>Diabetologia</i> , 2015, 58, 1759-1768.  | 2.9 | 73        |
| 113 | Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. <i>Diabetologia</i> , 2005, 48, 1872-1881.   | 2.9 | 72        |
| 114 | Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 499-508.   | 2.2 | 71        |
| 115 | Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. <i>Peptides</i> , 1998, 19, 1049-1053.  | 1.2 | 69        |
| 116 | Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). <i>European Heart Journal</i> , 2000, 21, 220-229.   | 1.0 | 69        |
| 117 | Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E849-E856.   | 1.8 | 65        |
| 118 | Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , 2017, 40, 966-972.   | 4.3 | 63        |
| 119 | Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance. <i>Diabetes</i> , 2001, 50, 776-784.  | 0.3 | 62        |
| 120 | Glucagon-like Peptide 1 (GLP-1) in the Treatment of Diabetes. <i>Hormone and Metabolic Research</i> , 2004, 36, 852-858.   | 0.7 | 61        |
| 121 | Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. <i>Peptides</i> , 2020, 125, 170183.   | 1.2 | 61        |
| 122 | Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as $\alpha$ -celso glycemica Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 945-954.  | 1.8 | 60        |
| 123 | Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1986-1993.   | 4.3 | 58        |
| 124 | Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. <i>Diabetes Care</i> , 2014, 37, 2647-2659.   | 4.3 | 58        |
| 125 | Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. <i>Trends in Endocrinology and Metabolism</i> , 2018, 29, 238-248.  | 3.1 | 55        |
| 126 | $\alpha$ -Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. <i>Diabetic Medicine</i> , 2005, 22, 470-476.  | 1.2 | 54        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | LEADER 3â€”Lipase and Amylase Activity in Subjects With Type 2 Diabetes. <i>Pancreas</i> , 2014, 43, 1223-1231.   | 0.5 | 54        |
| 128 | Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis. <i>Diabetes Care</i> , 2020, 43, 2303-2312.   | 4.3 | 54        |
| 129 | Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the <sc>DEVOTE</sc>, <sc>LEADER</sc> and <sc>SUSTAIN</sc>â€” cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1537-1547.  | 2.2 | 54        |
| 130 | Glucagon-Like Peptide 1 and its Potential in the Treatment of Non-Insulin-Dependent Diabetes Mellitus. <i>Hormone and Metabolic Research</i> , 1997, 29, 411-416.   | 0.7 | 53        |
| 131 | The novel dual glucoseâ€”dependent insulinotropic polypeptide and glucagonâ€”like peptideâ€”1 (<sc>GLP</sc>â€”1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective <sc>longâ€”acting GLP</sc>â€”1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1886-1891. | 2.2 | 53        |
| 132 | Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1128-1141.  | 1.2 | 53        |
| 133 | Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide. <i>BioDrugs</i> , 2003, 17, 93-102.   | 2.2 | 52        |
| 134 | Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2004, 18, 587-606.  | 2.2 | 52        |
| 135 | Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. <i>Diabetes Care</i> , 2018, 41, 1663-1671.  | 4.3 | 51        |
| 136 | Lack of Effect of Synthetic Human Gastric Inhibitory Polypeptide and Glucagon-Like Peptide 1 [7-36 Amide] Infused at Near-Physiological Concentrations on Pentagastrin-Stimulated Gastric Acid Secretion in Normal Human Subjects. <i>Digestion</i> , 1992, 52, 214-221.  | 1.2 | 49        |
| 137 | Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. <i>Acta Diabetologica</i> , 1993, 30, 39-45.  | 1.2 | 47        |
| 138 | Hypoglycemia due to Paraneoplastic Secretion of Insulin-Like Growth Factor-I in a Patient with Metastasizing Large-Cell Carcinoma of the Lung. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1600-1605.   | 1.8 | 47        |
| 139 | Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids. <i>Diabetes</i> , 2012, 61, 292-300.   | 0.3 | 47        |
| 140 | Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?. <i>European Journal of Endocrinology</i> , 2008, 158, 773-784.  | 1.9 | 45        |
| 141 | Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2 diabetic patients. , 1998, 15, 937-945.  |     | 43        |
| 142 | Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1579-1585.   | 1.5 | 43        |
| 143 | Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 213-222.                                 | 2.2 | 43        |
| 144 | Unraveling the Science of Incretin Biology. <i>European Journal of Internal Medicine</i> , 2009, 20, S303-S308.   | 1.0 | 43        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines—a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems. <i>Diabetic Medicine</i> , 2014, 31, 1078-1085.    | 1.2 | 43        |
| 146 | Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist. <i>Diabetes</i> , 2016, 65, 2440-2447. | 0.3 | 43        |
| 147 | GIP as a Potential Therapeutic Agent?. <i>Hormone and Metabolic Research</i> , 2004, 36, 859-866.   | 0.7 | 42        |
| 148 | Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. <i>Frontiers in Endocrinology</i> , 2021, 12, 645566.  | 1.5 | 42        |
| 149 | Chronic Reduction of Fasting Glycemia With Insulin Glargine Improves First- and Second-Phase Insulin Secretion in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 2048-2053.  | 4.3 | 41        |
| 150 | Incretins and their analogues as new antidiabetic drugs. <i>Drug News and Perspectives</i> , 2003, 16, 413.   | 1.9 | 40        |
| 151 | Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. <i>Regulatory Peptides</i> , 2004, 118, 89-97.  | 1.9 | 39        |
| 152 | Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 606-607.  | 2.9 | 39        |
| 153 | Incretin-based therapies: where will we be 50 years from now?. <i>Diabetologia</i> , 2015, 58, 1745-1750.   | 2.9 | 39        |
| 154 | Occurrence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events. <i>JAMA Cardiology</i> , 2019, 4, 1214.  | 3.0 | 39        |
| 155 | GIP and GLP-1: Stepsiblings Rather Than Monozygotic Twins Within the Incretin Family. <i>Diabetes</i> , 2019, 68, 897-900.  | 0.3 | 39        |
| 156 | Consensus report: definition and interpretation of remission in type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 2359-2366.   | 2.9 | 39        |
| 157 | Therapy of Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S73-S92.   | 0.6 | 38        |
| 158 | Long COVID—metabolic risk factors and novel therapeutic management. <i>Nature Reviews Endocrinology</i> , 2021, 17, 379-380.  | 4.3 | 38        |
| 159 | Critical evaluation of the “heated and” technique™ for obtaining “arterialized” venous blood: incomplete arterialization and alterations in glucagon responses. <i>Clinical Physiology</i> , 1992, 12, 537-552.   | 0.7 | 37        |
| 160 | Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?. <i>Diabetologia</i> , 2013, 56, 1878-1883.   | 2.9 | 36        |
| 161 | Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> , 2019, 42, 1912-1920.                      | 4.3 | 35        |
| 162 | Diagnostic Accuracy of an “Amended” Insulin-Glucose Ratio for the Biochemical Diagnosis of Insulinomas. <i>Annals of Internal Medicine</i> , 2012, 157, 767.  | 2.0 | 34        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1995, 268, E949-E955.  | 1.8 | 33        |
| 164 | Comparison of Pancreas-Transplanted Type 1 Diabetic Patients with Portal-Venous Versus Systemic-Venous Graft Drainage: Impact on Glucose Regulatory Hormones and the Growth Hormone/Insulin-Like Growth Factor-I Axis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1758-1766. | 1.8 | 32        |
| 165 | Confronting the Type 2 Diabetes Epidemic: the Emerging Role of Incretin-Based Therapies. <i>American Journal of Medicine</i> , 2010, 123, S2-S10.   | 0.6 | 32        |
| 166 | Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1-9.  | 1.8 | 32        |
| 167 | Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001706.  | 1.2 | 31        |
| 168 | Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards. <i>Diabetes Care</i> , 2020, 43, 2906-2909.  | 4.3 | 30        |
| 169 | Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 200-207.                           | 2.2 | 28        |
| 170 | Determinants of a normal (versus impaired) oral glucose tolerance after combined pancreas-kidney transplantation in IDDM patients. <i>Diabetologia</i> , 1996, 39, 462-468.   | 2.9 | 27        |
| 171 | Combined Pancreas and Kidney Transplantation in a Lean Type 2 Diabetic Patient. Effects on Insulin Secretion and Sensitivity. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2002, 110, 420-424.   | 0.6 | 27        |
| 172 | Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits. <i>Postgraduate Medicine</i> , 2009, 121, 5-15.   | 0.9 | 27        |
| 173 | Cloning and quantitative determination of the human Ca <sup>2+</sup> /calmodulin-dependent protein kinase II (CaMK II) isoforms in human beta cells. <i>Diabetologia</i> , 2000, 43, 465-473.   | 2.9 | 26        |
| 174 | Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. <i>Diabetes Research and Clinical Practice</i> , 2017, 131, 49-60.  | 1.1 | 26        |
| 175 | To be or not to be--an incretin or enterogastrone?. <i>Gut</i> , 2006, 55, 148-150.   | 6.1 | 25        |
| 176 | Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). <i>American Journal of Cardiology</i> , 2018, 121, 1467-1470.   | 0.7 | 25        |
| 177 | Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , 2018, 138, 1605-1607.   | 1.6 | 25        |
| 178 | GLP-1 analogues and insulin: sound the wedding bells?. <i>Nature Reviews Endocrinology</i> , 2011, 7, 193-195.  | 4.3 | 24        |
| 179 | Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2007, 10, 070509203705001-???  | 2.2 | 23        |
| 180 | Liraglutide and Glycaemic Outcomes in the LEADER Trial. <i>Diabetes Therapy</i> , 2018, 9, 2383-2392.   | 1.2 | 23        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 424-442.  | 3.1 | 23        |
| 182 | Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 465-468.  | 0.9 | 22        |
| 183 | Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1745-1751.  | 2.2 | 22        |
| 184 | Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1998, 106, 103-107.  | 0.6 | 21        |
| 185 | Preserved GLP-1 Effects in a Diabetic Patient with Cushing's Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2007, 115, 146-150.  | 0.6 | 21        |
| 186 | Defects in $\beta$ -Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals. <i>Diabetes Care</i> , 2017, 40, 1314-1322.   | 4.3 | 21        |
| 187 | Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 525-532.  | 2.2 | 21        |
| 188 | Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 2137-2145.   | 4.3 | 21        |
| 189 | Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 410.  | 1.8 | 21        |
| 190 | Role of Endogenously Released Cholecystokinin in Determining Postprandial Insulin Levels in Man: Effects of Loxiglumide, a Specific Cholecystokinin Receptor Antagonist. <i>Digestion</i> , 1992, 53, 189-199.   | 1.2 | 20        |
| 191 | Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 868-877.   | 2.2 | 20        |
| 192 | Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. <i>Diabetes Care</i> , 2017, 40, 647-654.  | 4.3 | 20        |
| 193 | Influence of an Antidiabetic Treatment with Sulfonylurea Drugs on Long-Term Survival after Acute Myocardial Infarction in Patients with Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2003, 111, 344-350.   | 0.6 | 19        |
| 194 | Comment to: Patti ME, McMahon G, Mun EC et al. (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. <i>Diabetologia</i> 48:2236-2240. <i>Diabetologia</i> , 2006, 49, 607-608. | 2.9 | 19        |
| 195 | The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms. <i>Diabetologia</i> , 2007, 50, 2413-2416.  | 2.9 | 19        |
| 196 | Incretin-based therapies in 2021 – Current status and perspectives for the future. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154843.   | 1.5 | 19        |
| 197 | The reduction in hepatic insulin clearance after oral glucose is not mediated by Gastric inhibitory polypeptide (GIP). <i>Regulatory Peptides</i> , 2003, 113, 95-100.   | 1.9 | 18        |
| 198 | Postoperative oral glucose tolerance and stimulated insulin secretion: a predictor of endocrine graft function more than 10 years after pancreas-kidney transplantation. <i>Transplantation</i> , 2003, 76, 1427-1431.   | 0.5 | 18        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | Glucagon-like peptide-1 in type 2 diabetes: the $\beta$ -cell and beyond. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 2-13.  | 2.2 | 18        |
| 200 | <sc>LEADER</sc> 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the <sc>L</sc>iraglutide <sc>E</sc>ffect and <sc>A</sc>ction in <sc>D</sc>iabetes: <sc>E</sc>valuation of cardiovascular outcome <sc>R</sc>esults (<sc>LEADER</sc>) trial: preliminary observations. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 477-486. | 2.2 | 18        |
| 201 | Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study. <i>Critical Care</i> , 2015, 19, 20.  | 2.5 | 18        |
| 202 | Prolonged Maximal Stimulation of Insulin Secretion in Healthy Subjects Does Not Provoke Preferential Release of Proinsulin. <i>Pancreas</i> , 1991, 6, 645-652.  | 0.5 | 17        |
| 203 | Comparison of hyperinsulinaemic clamp experiments using venous, $\tilde{\text{arterialized}}$ venous or capillary euglycaemia. <i>Clinical Physiology</i> , 1996, 16, 589-602.   | 0.7 | 17        |
| 204 | Proinsulin levels in patients with pancreatic diabetes are associated with functional changes in insulin secretion rather than pancreatic $\beta$ -cell area. <i>European Journal of Endocrinology</i> , 2010, 163, 551-558.   | 1.9 | 17        |
| 205 | Feedback suppression of meal-induced glucagon-like peptide-1 (<sc>GLP</sc>-1) secretion mediated through elevations in intact <sc>GLP</sc>-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1100-1109.                 | 2.2 | 17        |
| 206 | GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 963-964.   | 5.5 | 17        |
| 207 | Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardiovascular outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1327-1328.  | 2.2 | 17        |
| 208 | Absence of a Memory Effect for the Insulinotropic Action of Glucagon-like Peptide 1 (GLP-1) in Healthy Volunteers. <i>Hormone and Metabolic Research</i> , 2003, 35, 551-556.  | 0.7 | 16        |
| 209 | On the Effects of Glucagon-Like Peptide-1 on Blood Glucose Regulation in Normal and Diabetic Subjects. <i>Annals of the New York Academy of Sciences</i> , 1996, 805, 729-736.   | 1.8 | 16        |
| 210 | Absence of severe hyperinsulinemia after pancreas/kidney transplantation with peripheral venous drainage. <i>Transplantation Proceedings</i> , 1997, 29, 645-646.  | 0.3 | 15        |
| 211 | A hyperinsulinaemic, sequentially eu- and hypoglycaemic clamp test to characterize autonomous insulin secretion in patients with insulinoma. <i>European Journal of Clinical Investigation</i> , 2003, 27, 109-115.  | 1.7 | 15        |
| 212 | Longitudinal Changes in Fasting and Glucose-Stimulated GLP-1 and GIP in Healthy Older Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6201-6206.  | 1.8 | 15        |
| 213 | Importance of localization of insulinomas: a systematic analysis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2019, 26, 383-392.  | 1.4 | 15        |
| 214 | Consensus report: Definition and interpretation of remission in type 2 diabetes. <i>Diabetic Medicine</i> , 2022, 39, e14669.  | 1.2 | 15        |
| 215 | Individualised incretin-based treatment for type 2 diabetes. <i>Lancet, The</i> , 2010, 376, 393-394.  | 6.3 | 14        |
| 216 | Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. <i>Cardiovascular Diabetology</i> , 2019, 18, 116.   | 2.7 | 14        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 217 | A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers. <i>Acta Diabetologica</i> , 1997, 34, 230-234.   | 1.2 | 13        |
| 218 | Response to comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. <i>Diabetologia</i> 50:259â€“267. <i>Diabetologia</i> , 2007, 50, 1563-1564. | 2.9 | 13        |
| 219 | A randomised, controlled trial of self-monitoring of blood glucose in patients with type 2 diabetes receiving conventional insulin treatment. <i>Diabetologia</i> , 2014, 57, 868-877.   | 2.9 | 13        |
| 220 | Histological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretinâ€based therapies. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 1253-1262.  | 2.2 | 13        |
| 221 | A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 313, E284-E291.   | 1.8 | 13        |
| 222 | GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 262-264.   | 5.5 | 13        |
| 223 | Islet Amyloid in Patients With Diabetes Due to Exocrine Pancreatic Disorders, Type 2 Diabetes, and Nondiabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2595-2605.   | 1.8 | 13        |
| 224 | Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 1330-1339.  | 1.5 | 12        |
| 225 | The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. <i>Metabolism: Clinical and Experimental</i> , 2020, 103, 154031.  | 1.5 | 12        |
| 226 | Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII). <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 360-370.  | 1.3 | 12        |
| 227 | Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the <sc>LEADER</sc> and <sc>SUSTAIN</sc> 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2193-2198.   | 2.2 | 11        |
| 228 | Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. <i>Diabetologia</i> , 1995, 38, 720-725.  | 2.9 | 11        |
| 229 | A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome. <i>Acta Diabetologica</i> , 2003, 40, 163-172.  | 1.2 | 10        |
| 230 | Comparative evaluation of incretinâ€based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failureâ€. <i>Journal of Diabetes Investigation</i> , 2010, 1, 24-36.   | 1.1 | 10        |
| 231 | Fasting C-peptide and Related Parameters Characterizing Insulin Secretory Capacity for Correctly Classifying Diabetes Type and for Predicting Insulin Requirement in Patients with Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2016, 124, 148-156.  | 0.6 | 10        |
| 232 | Improvement in glycated haemoglobin evaluated by baseline body mass index: a metaâ€analysis of the liraglutide phase <sc>III</sc> clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 707-710.   | 2.2 | 10        |
| 233 | Sitagliptin plus basal insulin: simplifying in-hospital diabetes treatment?. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 83-85.   | 5.5 | 10        |
| 234 | Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on mealâ€related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 599-611.   | 2.2 | 10        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 235 | Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 479-488.   | 4.3 | 10        |
| 236 | The design of the liraglutide clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 4-12.   | 2.2 | 9         |
| 237 | Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 721-724. | 2.2 | 9         |
| 238 | Metabolomic linkage reveals functional interaction between glucose-dependent insulinotropic polypeptide and ghrelin in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2011, 301, E608-E617.   | 1.8 | 8         |
| 239 | Effect of Exogenous Intravenous Administrations of GLP-1 and/or GIP on Circulating Pro-Atrial Natriuretic Peptide in Subjects With Different Stages of Glucose Tolerance. <i>Diabetes Care</i> , 2015, 38, e7-e8.   | 4.3 | 8         |
| 240 | Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2450-2458.   | 2.2 | 8         |
| 241 | Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal Variability. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 1262-1272.                                | 1.3 | 8         |
| 242 | Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2344-2353.                  | 2.2 | 8         |
| 243 | Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls. <i>World Journal of Gastroenterology</i> , 2006, 12, 1874.   | 1.4 | 8         |
| 244 | Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.   | 2.7 | 8         |
| 245 | Basal and nutrient-stimulated pancreatic and gastrointestinal hormone concentrations in type-1-diabetic patients after successful combined pancreas and kidney transplantation. <i>The Clinical Investigator</i> , 1992, 70, 40-48.                                       | 0.6 | 7         |
| 246 | Effect of portal glucose sensing on incretin hormone secretion in a canine model. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E244-E249.  | 1.8 | 7         |
| 247 | Measurement of Gastric Emptying Using a 13C-octanoic Acid Breath Test with Wagner-Nelson Analysis and Scintigraphy in Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, 751-757.  | 0.6 | 7         |
| 248 | Six Methods for the Determination of C-Peptide Evaluated. <i>Clinical Chemistry and Laboratory Medicine</i> , 1999, 37, 745-51.   | 1.4 | 6         |
| 249 | Impact of Exogenous Hyperglucagonemia on Postprandial Concentrations of Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4061-4065.  | 1.8 | 6         |
| 250 | Pancreatitis and incretin-based drugs: clarity or confusion?. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 92-93.  | 5.5 | 6         |
| 251 | Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy – A Retrospective Observational Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 663-671.                       | 0.6 | 6         |
| 252 | Self-Monitoring of Blood Glucose in Diabetes Mellitus. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2009, 106, 587-94.   | 0.6 | 6         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 253 | Genetic Determinants Predicting Efficacy of Glucose-Lowering Drugs?: A long way to go .... Diabetes Care, 2010, 33, 2123-2125.   | 4.3  | 5         |
| 254 | Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial. Diabetes and Vascular Disease Research, 2016, 13, 286-298. | 0.9  | 5         |
| 255 | A case series of verrucae vulgares mimicking hyperkeratosis in individuals with diabetic foot ulcers. Diabetic Medicine, 2017, 34, 1165-1168.  | 1.2  | 5         |
| 256 | Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. International Journal of Clinical Practice, 2018, 72, e13240.                                       | 0.8  | 5         |
| 257 | The relationship between plasma GIP and GLP-1 levels in individuals with normal and impaired glucose tolerance. Acta Diabetologica, 2020, 57, 583-587.   | 1.2  | 5         |
| 258 | Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S80-S112.   | 0.6  | 5         |
| 259 | SA0010 EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. Nephrology Dialysis Transplantation, 2019, 34, .                    | 0.4  | 4         |
| 260 | FP483 EFFECTS OF SEMAGLUTIDE AND LIRAAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation, 2019, 34, .  | 0.4  | 4         |
| 261 | Pioneering oral peptide therapy for patients with type 2 diabetes. Lancet Diabetes and Endocrinology, 2019, 7, 500-502.  | 5.5  | 4         |
| 262 | Owning a Dog as a Determinant of Physical Activity and Metabolic Control in Patients With Type 1 and Type 2 Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 379-384.                                   | 0.6  | 4         |
| 263 | Novel approaches to treating type 2 diabetes. Diabetologia, 2016, 59, 227-228.   | 2.9  | 3         |
| 264 | FP482 EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation, 2019, 34, .  | 0.4  | 3         |
| 265 | No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects. Peptides, 2020, 125, 170176.         | 1.2  | 3         |
| 266 | Prediction of Individual Basal Rate Profiles From Patient Characteristics in Type 1 Diabetes on Insulin Pump Therapy. Journal of Diabetes Science and Technology, 2020, 15, 193229682097269.   | 1.3  | 3         |
| 267 | Voices: Insulin and beyond. Cell Metabolism, 2021, 33, 692-699.  | 7.2  | 3         |
| 268 | Another milestone in the evolution of GLP-1-based diabetes therapies. Nature Medicine, 2021, 27, 952-953.  | 15.2 | 3         |
| 269 | DOES GLUCAGON STIMULATION PREDICT ORAL GLUCOSE TOLERANCE IN PATIENTS AFTER SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION?1. Transplantation, 2000, 70, 545-547.   | 0.5  | 3         |
| 270 | Understanding the restrictions in the prescription and use of potentially beneficial diabetes medications associated with low socio-economic status. Lancet Regional Health - Europe, The, 2022, 14, 100318.                               | 3.0  | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 271 | Insulin clearance and incretin hormones following oral and $\alpha$ -isoglycemic intravenous glucose in type 2 diabetes patients under different antidiabetic treatments. <i>Scientific Reports</i> , 2022, 12, 2510.  | 1.6 | 3         |
| 272 | Prediction of glucose tolerance with glucagon stimulation in pancreas transplanted patients. <i>Transplantation Proceedings</i> , 1997, 29, 3122-3123.   | 0.3 | 2         |
| 273 | Modified hyperinsulinaemic, eu- and hypoglycaemic clamp technique using lispro-insulin for insulinoma diagnostic. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2001, 109, 397-401.  | 0.6 | 2         |
| 274 | Orlistat Augments Postprandial Increases in Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Damci et al.. <i>Diabetes Care</i> , 2004, 27, 2770-2770.   | 4.3 | 2         |
| 275 | Glycaemic Rises after Waking Up in Response to an Alarm Clock in Type 1-diabetic Patients Analysed with Continuous Glucose Monitoring (GlucoDay <sup>®</sup> S). <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2011, 119, 56-58.   | 0.6 | 2         |
| 276 | In vivo effect of glucose-dependent insulinotropic peptide (GIP) on the gene expression of calcitonin peptides in human subcutaneous adipose tissue. <i>Regulatory Peptides</i> , 2012, 179, 29-32.  | 1.9 | 2         |
| 277 | A1C Improvement with Liraglutide Evaluated by Baseline BMI. <i>Canadian Journal of Diabetes</i> , 2013, 37, S35-S36.   | 0.4 | 2         |
| 278 | Incretin mimetics and insulin $\alpha$ closing the gap to normoglycaemia. <i>Nature Reviews Endocrinology</i> , 2016, 12, 689-690.   | 4.3 | 2         |
| 279 | Break point instead of ACE: acarbose, post-load glycaemic excursions, and cardiovascular events. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 843-845.  | 5.5 | 2         |
| 280 | Reply to: Autonomic dyshomeostasis in patients with diabetes mellitus during COVID-19. <i>Nature Reviews Endocrinology</i> , 2021, 17, 189-190.  | 4.3 | 2         |
| 281 | 58-OR: The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist. <i>Diabetes</i> , 2019, 68, 58-OR.   | 0.3 | 2         |
| 282 | Liraglutide Effects in Insulin-Treated Patients in LEADER. <i>Diabetes</i> , 2018, 67, 438-P.  | 0.3 | 2         |
| 283 | Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. <i>Lancet</i> , 2002, 360, 257.   | 6.3 | 1         |
| 284 | Preface. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, vii.   | 2.2 | 1         |
| 285 | Diagnostic Accuracy of an $\alpha$ -Amended $\alpha$ -Insulin $\alpha$ Glucose Ratio for the Biochemical Diagnosis of Insulinomas. <i>Annals of Internal Medicine</i> , 2013, 158, 501.  | 2.0 | 1         |
| 286 | The insulinotropic effect of pulsatile compared with continuous intravenous delivery of GLP-1. <i>Diabetologia</i> , 2016, 59, 966-969.  | 2.9 | 1         |
| 287 | Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial. <i>Canadian Journal of Diabetes</i> , 2017, 41, S5.  | 0.4 | 1         |
| 288 | Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. <i>Diabetes Care</i> 2019;42:1912-1920. <i>Diabetes Care</i> , 2020, 43, e30-e31. | 4.3 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 289 | SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?. <i>Endocrinology</i> , 2020, 161, .  | 1.4 | 1         |
| 290 | 993-P: A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, 993-P.  | 0.3 | 1         |
| 291 | Effects of single and combined infusions of human biosynthetic proinsulin and insulin on glucose metabolism and on plasma hormone concentrations in euglycaemic clamp experiments. <i>Hormone and Metabolic Research Supplement Series</i> , 1988, 18, 60-7.  | 0.2 | 1         |
| 292 | Has a single blood glucose estimation on admission to hospital any prognostic value for acute pancreatitis?. <i>Gastroenterology</i> , 2000, 118, A1143.  | 0.6 | 0         |
| 293 | For Insulinomas, No Place to Hide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4125-4126.   | 1.8 | 0         |
| 294 | Basal rate tests (24-hour fasts) performed in type 1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles: <scp>A</scp> randomized controlled prospective trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 783-790. | 2.2 | 0         |
| 295 | Risk of hypoglycaemia associated with professional, recreational, and traffic-related activities in patients with type 2 diabetes: a cross-sectional study by questionnaire. <i>Acta Diabetologica</i> , 2020, 57, 965-972.   | 1.2 | 0         |
| 296 | Incretin Hormone Release Does Not Involve Hepatic Portal Vein Glucose Sensors. <i>Diabetes</i> , 2018, 67, 1961-P.  | 0.3 | 0         |
| 297 | 55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4. <i>Diabetes</i> , 2019, 68, .  | 0.3 | 0         |
| 298 | Acute effects of linagliptin on intact and total glucagon-like peptide 1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 806-815.                                       | 2.2 | 0         |
| 299 | Comment: Type 1 diabetes and oral health: Findings from the Epidemiology of Diabetes Interventions and Complications (EDIC) study. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108146.   | 1.2 | 0         |
| 300 | Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective. <i>Diabetes and Metabolism Journal</i> , 2022, , .  | 1.8 | 0         |
| 301 | Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2). <i>Diabetologie Und Stoffwechsel</i> , 2022, , .   | 0.0 | 0         |